Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
Sarepta Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Sarepta Therapeutics's pe ratio was 43.7× on Jul 31, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 43.7× | +17.0 |
| 2025 | Apr 30, 2025 | 26.7× | −73.0 |
| 2024 | Dec 31, 2024 | 99.7× | – |
See a number that looks wrong?